Price (delayed)
$5.61
Market cap
$458.98M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.02
Enterprise value
$371.86M
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a
There are no recent dividends present for EDIT.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.